title: Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
abstract: OBJECTIVE
  This prospective, randomized, placebo-controlled, double-blind clinical trial was performed to analyze the effect of atorvastatin compared with placebo on the occurrence of a 6-month composite of cardiovascular events after vascular surgery. Cardiovascular complications are the most important cause of perioperative morbidity and mortality among patients undergoing vascular surgery. Statin therapy may reduce perioperative cardiac events through stabilization of coronary plaques.
  
  
  METHODS
  One hundred patients were randomly assigned to receive 20 mg atorvastatin or placebo once a day for 45 days, irrespective of their serum cholesterol concentration. Vascular surgery was performed on average 30 days after randomization, and patients were prospectively followed up over 6 months. The cardiovascular events studied were death from cardiac cause, nonfatal myocardial infarction, unstable angina, and stroke.
  
  
  RESULTS
  Fifty patients received atorvastatin, and 50 received placebo. During the 6-month follow-up primary end points occurred in 17 patients, 4 in the atorvastatin group and 13 in the placebo group. The incidence of cardiac events was more than three times higher with placebo (26.0%) compared with atorvastatin (8.0%; P =.031). The risk for an event was compared between the groups with the Kaplan-Meier method, as event-free survival after vascular surgery. Patients given atorvastatin exhibited a significant decrease in the rate of cardiac events, compared with the placebo group, within 6 months after vascular surgery (P =.018).
  
  
  CONCLUSIONS
  Short-term treatment with atorvastatin significantly reduces the incidence of major adverse cardiovascular events after vascular surgery.
authors.affiliation: Heart Institute and Vascular Surgery Department, University of São Paulo Medical School, São Paulo, Brazil. anaidurazzo@uol.com.br
authors.forename: Anai E S
authors.initials: AE
authors.lastname: Durazzo
authors.forename: Fábio S
authors.initials: FS
authors.lastname: Machado
authors.forename: Dimas T
authors.initials: DT
authors.lastname: Ikeoka
authors.forename: Cláudia
authors.initials: C
authors.lastname: De Bernoche
authors.forename: Maristela C
authors.initials: MC
authors.lastname: Monachini
authors.forename: Pedro
authors.initials: P
authors.lastname: Puech-Leão
authors.forename: Bruno
authors.initials: B
authors.lastname: Caramelli
mesh_terms: D000368:Aged; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D010349:Patient Compliance; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors; D014656:Vascular Surgical Procedures
chemical_list: D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin